Clinical Trial Ancillary Supplies: Managing the Forgotten Half of the Supply Chain

A patient arrives for an infusion visit. The investigational product is on the shelf, in date, released, and correctly assigned by the IRT. The dose still doesn't happen — because the site ran out of the 0.2-micron in-line filter the pharmacy manual requires, and the only validated filter is on back-order.

That scenario plays out constantly, and it almost never makes it into a lessons-learned deck, because it doesn't feel like a supply failure. It feels like procurement. But from the patient's chair, a missing filter and a missing kit are the same thing: no dose today. Ancillary supplies are the half of the clinical supply chain that nobody owns by default — and that is precisely why they fail.

What counts as an ancillary supply?

Ancillary supplies are everything a site needs to run the protocol that isn't the investigational product itself. In practice they fall into a handful of families:

• Administration materials — infusion sets, in-line filters, IV bags, syringes, needles, closed-system transfer devices, oral dosing syringes.
• Co-medications and rescue medications — premedications (antihistamines, steroids, antiemetics), rescue therapy, and background therapy the protocol mandates. In the EU these are auxiliary medicinal products under the Clinical Trials Regulation, with their own labeling rules when unauthorised.
• Diagnostic and sampling materials — central lab kits, biopsy kits, PK sample tubes, shipping materials for specimens.
• Patient-facing devices — eDiaries, glucometers, inhaler spacers, wearables, dosing cups.
• Storage and monitoring equipment — temperature loggers, qualified refrigerators or freezers loaned to sites, dry shippers.
• Patient materials — dosing cards, instructions for use, cool bags for take-home supply.

Some of these overlap with comparators and co-therapies — the line between "ancillary" and "comparator" is often blurry. Our post on comparator sourcing covers the drug side; this one covers everything else.

Why do ancillary supplies cause so many dosing delays?

Because they sit in the gap between functions. Clinical supply owns the IMP. Clinical operations owns the sites. Procurement owns purchasing. The central lab owns lab kits. Nobody owns the list — the complete bill of materials a site needs on visit day — so nobody notices the missing line until a coordinator does.

A few structural features make the gap worse:

1. Ancillaries have the same failure modes as drug, without the same controls. They expire. They have regulatory status (a device may need a CE mark or a specific marketing status in-country). They need import classification. But they rarely get a forecast, a buffer, or a place in the IRT.
2. Validated compatibility creates single sources. If your stability or compatibility study validated one specific filter, tubing material, or IV bag type, you can't swap in a local equivalent. A generic-looking consumable quietly becomes a single point of failure.
3. Country availability is uneven. A syringe that's commodity in the US may be unavailable, differently specified, or unaffordable in half your countries.
4. Customs treats them differently. Devices and lab kits often clear under different codes and rules than investigational drug — and a shipment that mixes them can be held for the slowest item. We've written about customs delays for drug; ancillaries add their own layer.

Should the sponsor supply ancillaries or let sites source them locally?

This is the central decision, and it should be made item by item, not as a blanket policy. Central supply gives you control and standardisation; local sourcing gives you speed, lower freight cost, and simpler customs. The right answer depends on what the item touches.

• Compatibility with the IMP was validated — Points toward sponsor-supplied: ✔ Specific brand/spec required
• Blinding depends on it (e.g., matched IV bags, overlays) — Points toward sponsor-supplied: ✔
• Data consistency matters (same device across sites) — Points toward sponsor-supplied: ✔ eDiaries, glucometers, lab kits
• Item is commodity and widely available in-country — Points toward site-sourced: ✔
• Freight or import cost exceeds item value — Points toward site-sourced: ✔
• Site reimbursement process exists and is fast — Points toward site-sourced: ✔
• Item is short-dated or temperature-sensitive — Points toward sponsor-supplied: Case by case; Points toward site-sourced: Case by case

A common hybrid: sponsor supplies anything validated, blinding-relevant, or data-generating; sites source commodities against a written specification and are reimbursed. The key word is written. "Standard infusion set" in a pharmacy manual isn't a specification — material, pore size, and length are.

How do you forecast ancillary demand?

Ancillaries don't follow the IMP forecast one-to-one, and treating them as a fixed ratio is where most overage and most stock-outs come from. Each item has its own demand driver:

• Per dosing visit — administration sets, filters, premedications.
• Per patient — devices, eDiaries, dosing cards, cool bags.
• Per sample timepoint — lab and PK kits, which follow the assessment schedule rather than the dosing schedule.
• Per site — loaned equipment, loggers, starter stock.

Build the ancillary forecast off the same enrollment scenarios as the drug forecast, but with the right driver for each item. Then layer in the things that are unique to ancillaries: supplier minimum order quantities, lead times that can exceed the IMP's, and shelf lives that are sometimes shorter than the drug's. Lab kits are a notorious example — kit components can expire well before the study ends, which puts them squarely inside your expiry management process, whether you planned it or not.

What should an ancillary management process include?

The sponsors who rarely lose a visit to a missing consumable tend to run a simple, disciplined playbook:

1. An ancillary bill of materials at protocol stage. Walk every visit in the schedule of assessments and list every physical item it requires. This takes an afternoon and prevents months of firefighting.
2. A named owner per item. Clinical supply, the central lab, the CRO, or the site — written down, not assumed.
3. A specification and approved sources for every item, with alternates pre-qualified where compatibility allows.
4. A country matrix showing, per item and country, whether it's central or local, and what regulatory or import status it needs.
5. Tracking proportional to criticality. Critical items (validated filters, blinding materials) can be tracked in the IRT alongside drug. Commodities can be managed by periodic site inventory checks.
6. Expiry and returns rules that mirror the drug process for anything short-dated or regulated.
7. A place in vendor oversight. Device suppliers and kit vendors belong inside your vendor governance cadence, not outside it.

What does poor ancillary planning actually cost?

The invoice-level cost is modest: expedited freight for a box of filters, over-ordered kits written off at close-out. The real cost is in visits. A missed or delayed dose is a protocol deviation, a potential dropout, and — in dose-intensive studies — a data-quality issue. Across a large program, ancillary-driven deviations can quietly rival IMP stock-outs. They're just categorised as site issues, so they never reach the supply budget conversation. We cover the full cost picture in where the supply budget actually goes.